Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
Authors
Keywords
Plasma cells, Bone marrow cells, Multiple myeloma, Flow cytometry, Antibodies, Hemodilution, Myelomas, Sequence analysis
Journal
PLoS One
Volume 14, Issue 3, Pages e0211600
Publisher
Public Library of Science (PLoS)
Online
2019-03-23
DOI
10.1371/journal.pone.0211600
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunoglobulin gene analysis as a tool for investigating human immune responses
- (2018) Deborah Dunn-Walters et al. IMMUNOLOGICAL REVIEWS
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions
- (2018) Caleb Ho et al. SEMINARS IN HEMATOLOGY
- MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool
- (2018) Ola Landgren SEMINARS IN HEMATOLOGY
- Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
- (2018) Mikhail Roshal SEMINARS IN HEMATOLOGY
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone
- (2018) Dickran Kazandjian et al. JAMA Oncology
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates
- (2017) José Antonio Delgado et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status
- (2017) Dara S. Ross et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
- (2017) J Martinez-Lopez et al. LEUKEMIA
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Myeloma minimal residual disease testing in the United States: Evidence of improved standardization
- (2016) Dalia Salem et al. AMERICAN JOURNAL OF HEMATOLOGY
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias
- (2016) Marvyn T. Koning et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
- (2016) N Bolli et al. Blood Cancer Journal
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside
- (2015) Sham Mailankody et al. Nature Reviews Clinical Oncology
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
- (2013) A. Flanders et al. BLOOD
- Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
- (2013) M Ladetto et al. LEUKEMIA
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- IgBLAST: an immunoglobulin variable domain sequence analysis tool
- (2013) Jian Ye et al. NUCLEIC ACIDS RESEARCH
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
- (2009) M Brüggemann et al. LEUKEMIA
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
- (2008) A. C. Rawstron et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now